(318) suggested that HSPA5-GPX4 pathway modulation to contribute to chemoresistance in pancreatic cancer cells against gemcitabine, and blocking of HSPA5 or GPX4 gene expression potentially reversing this resistance. This evidence concerns the gene GPX4 and familial pancreatic carcinoma.